• $390.5M
    Market Cap
  • 70.43%
    1-Year Change
  • Biotechnology
    Industry

Key Performance

More
  • Earnings Score: N/A
  • Momentum Score: 60
  • True Yield: N/A
  • Financial Health Score: N/A
TradeSmith Loading

Latest Research & News

Vitiligo Clinical Trial Pipeline Accelerates as 18+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

Over 18 pharmaceutical companies are developing targeted therapies for vitiligo, with promising pipeline drugs showing potential to transform treatment options beyond conventional approaches like corticosteroids and phototherapy.

08/14/2025, 1:00 PM • GlobeNewswire

Forte and Sequence Partner to Power Web3 Monetization Through Integrated Payment Infrastructure

Forte, through its subsidiary LemmaX, partnered with Sequence to integrate FortePay as a comprehensive payment infrastructure, enabling developers to process multi-chain payments with enhanced compliance and user experience across blockchain networks.

07/04/2025, 6:00 AM • GlobeNewswire

Peers

Statistics

More
Day Range
$16.67
$18.59
$17.00
1-Year Range
$9.45
$35.53
$17.00
Latest Close$17.00
Change
-$1.17 (-6.91%)
Volume354,630
Market Cap$390.5M
Shares Outstanding20.5M
Enterprise Value$332.3M

Information as of 06/03/2026

Company Profile

FORTE BIOSCIENCES INC
https://www.fortebiorx.com
$390.5M
Market Cap
-$75.9M
Net Income
Sector: Healthcare
Industry: Biotechnology
3060 Pegasus Park Drive, Dallas, TX, United States, 75247
310 618 6994

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as celiac disease, vitiligo, alopecia areata, and type 1 diabetes. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Key Executives

  • Paul A. Wagner
  • Antony A. Riley
  • Barbara K. Finck
  • Christopher Roenfeldt

Current Ownership Distribution

  • Institutions149.9M (77.78%)
  • Mutual Funds39.1M (20.31%)
  • Insiders3.7M (1.91%)
  • Other0 (0.00%)